Osteoprotegerin/TNFRSF11B Antibody [Alexa Fluor® 532]

• Applications: WB, IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 532

Osteoprotegerin/TNFRSF11B Antibody [Alexa Fluor® 532] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Osteoprotegerin/TNFRSF11B
  Glu22-Leu401
  Accession # AAB53709
• Specificity: Detects human Osteoprotegerin/TNFRSF11B in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant mouse Osteoprotegerin is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Osteoprotegerin (OPG)/Osteoclastogenesis Inhibitory Factor (OCIF) is a member of the tumor necrosis factor receptor superfamily that lacks any apparent cell‑association motifs and exists as a soluble secreted protein. In the TNF superfamily nomenclature, OPG is referred to as TNFRSF11B. OPG was originally isolated by sequence homology as a TNF receptor family protein during a fetal rat intestine cDNA-sequencing project and subsequently shown to be involved in the regulation of bone density. OCIF was initially purified from the conditioned medium of human embryonic fibroblasts based on its ability to inhibit osteoclast development. Comparison of the amino acid (aa) sequences of human OPG and OCIF proteins revealed their identity. Human OPG/OCIF cDNA encodes a 401 aa residue precursor protein with a 21 aa residue putative signal peptide that is removed to generate the mature soluble protein. The amino-terminal half of OPG contains four cysteine-rich repeats characteristic of TNF receptor family members. The 204 residues of the carboxy-terminal OPG/OCIF was found to contain two death domain homologous regions in tandem. Human and mouse OPG share approximately 84% and 94% amino acid sequence identity, respectively, with the rat OPG. Natural OPG/OCIF has been found to exist predominantly as disulfide-linked dimers. Two TNF superfamily ligands, including the membrane proteins OPG ligand/TRANCE (tumor necrosis factor-related activation-induced cytokine)/ODF (osteoclast differentiation factor)/RANKL (receptor activator of NF kappa B ligand) and TRAIL (TNF-related apoptosis‑inducing ligand)/APO-2 ligand, have been shown to be the cellular ligands for OPG/OCIF. Each of these ligands has been shown to interact with additional TNF receptor family members, including RANK (with TRANCE) and TRAIL receptors 1 - 4 (with TRAIL). The roles of these receptor-ligands in osteoclastogenesis, apoptosis and in the immune system remains to be elucidated.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.